ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Earnings of -$0.09 Per Share
Equities analysts expect that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will announce earnings per share of ($0.09) for the current quarter, Zacks reports. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.10). ZIOPHARM Oncology reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive year over year growth rate of 40%. The firm is expected to announce its next earnings report on Thursday, May 9th.
On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.35) to ($0.26). For the next year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for ZIOPHARM Oncology.
A number of equities research analysts have issued reports on ZIOP shares. BidaskClub upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Friday, December 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $4.92.
Shares of ZIOP traded down $0.07 during trading hours on Monday, hitting $4.00. The company had a trading volume of 1,805,803 shares, compared to its average volume of 1,738,243. The firm has a market capitalization of $660.52 million, a PE ratio of -8.33 and a beta of 2.59. ZIOPHARM Oncology has a 12 month low of $1.56 and a 12 month high of $5.00.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Story: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.